Sort   by:  
 Page size 
UnknownAssociation of Toll-like receptor 7 variants with life-threatening COVID-19 disease in males: findings from a nested case-control study.
Not available
S-EPMC7987337 | biostudies-literature
UnknownA genome-wide association study for survival from a multi-centre European study identified variants associated with COVID-19 risk of death.
Not available
S-EPMC10847137 | biostudies-literature
UnknownContribution of ultrarare variants in mTOR pathway genes to sporadic focal epilepsies.
Not available
S-EPMC6414475 | biostudies-literature
UnknownProtective Role of a TMPRSS2 Variant on Severe COVID-19 Outcome in Young Males and Elderly Women.
Not available
S-EPMC8073081 | biostudies-literature
UnknownDeformation Imaging by Strain in Chronic Heart Failure Over Sacubitril-Valsartan: A Multicenter Echocardiographic Registry.
Not available
S-EPMC10053272 | biostudies-literature
UnknownDurability of benralizumab effectiveness in severe eosinophilic asthma patients with and without chronic rhinosinusitis with nasal polyps: a <i>post hoc</i> analysis from the ANANKE study.
Not available
S-EPMC11965627 | biostudies-literature
UnknownClinical remission in patients with severe eosinophilic asthma treated with benralizumab over 24 months: Post hoc analysis of the ANANKE study.
Not available
S-EPMC12830156 | biostudies-literature
UnknownLong-term effectiveness of benralizumab in severe eosinophilic asthma patients treated for 96-weeks: data from the ANANKE study.
Not available
S-EPMC10200058 | biostudies-literature
UnknownSwitching from one biologic to benralizumab in patients with severe eosinophilic asthma: An ANANKE study post hoc analysis.
Not available
S-EPMC9478391 | biostudies-literature
UnknownClinical Features and Efficacy of Benralizumab in Patients with Blood Eosinophil Count Between 300 and 450 Cells/mm3: A Post Hoc Analysis from the ANANKE Study.
Not available
S-EPMC9661992 | biostudies-literature
Sort   by:  
 Page size